{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:52:07Z","timestamp":1767423127590,"version":"3.40.5"},"reference-count":39,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To classify the molecular subtypes of Paget's disease of the breast, and then compare them with general breast cancer to get deeper understanding of this disease and offer better management of associate patients in clinical decisions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used immunohistochemistry to examine 42 cases of this disease by antibodies against estrogen and progesterone receptors, Ki\u201067, as well as human epidermal growth factor receptor 2 (HER\u20102). Due to damage and loss of specimens, etc., we obtained 36 pathological specimens from the 42 patients. For 30 of 36 pathological specimens (83.3%), we obtained a complete molecular subtype. Cause the other 6 pathological specimens have missing immunohistochemistry items. For patients with bilateral breast cancer, only information on the side with PDB is listed. For patients with recurrence, only information on the first onset was included. We finally compared and studied the molecular subtype of 26 samples. We calculated the relative frequencies of molecular subtypes including luminal A, luminal B, HER\u20102\u2010enriched, and basal\u2010like and compared them between PDB and general breast carcinomas in other studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The luminal A and B subtype were found, respectively, in 3 (11.5%) and 6 (23.1%) of all patients, and 15 cases of HER\u20102\u2010enriched subtype was detected (57.7%). In addition, 2 (7.7%) showed a basal\u2010like subtype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The molecular subtypes of common breast cancer and PDB\u2010associated breast cancer differ. Luminal subtypes are the most common in the former, while within our samples HER\u20102 positive subtype was the highest in PDB\u2010associated breast carcinoma. With further understanding of this disease, rational therapies will be applied in different patients and cures for PDB and PDB\u2010associated carcinoma will be achieved.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6066","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:04:18Z","timestamp":1683871458000},"page":"14104-14111","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Using immunohistochemistry to classify the molecular subtypes of Paget's disease of the breast"],"prefix":"10.1002","volume":"12","author":[{"given":"Yujiao","family":"Cai","sequence":"first","affiliation":[{"name":"Department of General Surgery Capital Medical University, Beijing Friendship Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongquan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery Capital Medical University, Beijing Friendship Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Nangong","sequence":"additional","affiliation":[{"name":"Department of General Surgery Capital Medical University, Beijing Friendship Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology Capital Medical University, Beijing Friendship Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-6235","authenticated-orcid":false,"given":"Zhu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of General Surgery Capital Medical University, Beijing Friendship Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/whe.09.23"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02154.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29687"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2226-5"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.06.015"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22137"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0344-0338(11)80085-3"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2006.06.010"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.317115070"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2661-4"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.4103\/1477-3163.90676"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2010.03665.x"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2011.07.010"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11337"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/651507"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1245\/aso.2005.05.026"},{"key":"e_1_2_13_18_1","unstructured":"EttingerD AkerleyW BorghaeiH.NCCN Clinical Practice Guidelines in Oncology.2013."},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2007.00477.x"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.53.10.742"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2008.01053.x"},{"issue":"6","key":"e_1_2_13_22_1","first-page":"396","article-title":"Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB\u20102 and cyclin D1","volume":"50","author":"Mrhalova M","year":"2003","journal-title":"Neoplasma"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt303"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2019.5.23967"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2011.05.010"},{"issue":"10","key":"e_1_2_13_26_1","first-page":"19616","article-title":"Diagnosis and treatment of Paget's disease of the breast: an analysis of 72 cases","volume":"8","author":"Song Q","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci57100"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-07-4082"},{"issue":"1","key":"e_1_2_13_29_1","first-page":"647","article-title":"HER\u20102\/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab\u2010based therapy","volume":"26","author":"Pectasides D","year":"2006","journal-title":"Anticancer Res"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-09-1735"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08489"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds248"},{"issue":"1","key":"e_1_2_13_33_1","first-page":"17","article-title":"Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast","volume":"39","author":"Lester T","year":"2009","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10638"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.13141"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061455"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0578-OA"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800437"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pdm.0000213456.30151.5b"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.12463"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T19:41:38Z","timestamp":1692301298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/cam4.6066"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6066","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"2022-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}